Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +174 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining combination chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus rituximab in treating patients who h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +20 locations
Conditions: Lymphoma
Register for Updates
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
NCT00773188
Completed
This single arm study will assess the feasibility of use, safety and tolerability of Avastin(bevacizumab) in combination with chemoradiation therapy in patients with locally advanced unresectable non-squamous non-small cell lung cancer.An initial cohort of patients will receive Avastin 7.5mg/kg iv every 3 weeks, in combination with concurrent thoracic radiation for 6.6 weeks and chemotherapy (cisplatin 75 mg/m2 iv and vinorelbine 15mg/m2 iv administered according to a standard treatment protocol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Calgary, Alberta +3 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT00806923
Completed
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Bahia Blanca, Not set +153 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: City of Hope National Medical Center, Duarte, California +54 locations
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Register for Updates
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00003299
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and etoposide alone in treating patients with extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus etoposide with or without paclitaxel in treating patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +19 locations
Conditions: Lung Cancer
Register for Updates
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
NCT00627835
Withdrawn
The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced squamous cell carcinomas of the head and neck (SCCHN)patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2016
Locations: BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia
Conditions: Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Register for Updates
Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer
NCT00002998
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +19 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
NCT00026403
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have locally advanced pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/12/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +25 locations
Conditions: Pancreatic Cancer
Register for Updates
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
NCT00072215
Terminated
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, cisplatin, paclitaxel, and vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide and cisplatin are more effective when combined with paclitaxel or vinblastine in treating germ cell tumors. PURPOSE: This randomized phase III trial is studying paclitaxel, ifosfamide, and cisplatin to see how well they work compared to vinblastine, ifosfamide, and cisplatin... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/01/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +78 locations
Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Register for Updates
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT01737008
Completed
This is a phase 1 study of the drug dacomitinib with radiotherapy, with or without chemotherapy, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Dacomitinib is an oral drug, which is found to be active in SCCHN patients, blocks a receptor called the epidermal growth factor receptor (EGFR). By blocking signals for cancer cells to grow, it is believed to stop or slow the growth of tumor cells. The dose escalation phase will find the best dose as well as determine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2016
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates